000102241 001__ 102241
000102241 005__ 20210902121805.0
000102241 0247_ $$2doi$$a10.1016/j.ejpb.2020.05.025
000102241 0248_ $$2sideral$$a118130
000102241 037__ $$aART-2020-118130
000102241 041__ $$aeng
000102241 100__ $$0(orcid)0000-0002-0272-3152$$aGámez-Herrera, E.
000102241 245__ $$aDrug-eluting wound dressings having sustained release of antimicrobial compounds
000102241 260__ $$c2020
000102241 5060_ $$aAccess copy available to the general public$$fUnrestricted
000102241 5203_ $$aWound healing is a complex and costly public health problem that should be timely addressed to achieve a rapid and adequate tissue repair avoiding or even eliminating potential pathogenic infection. Chronic infected non-healing wounds represent a serious concern for health care systems. Efficient wound dressings with tailored therapy having the best response and highest safety margin for the management of chronic non-healing wounds are still needed. The use of novel wound dressing materials has emerged as a promising tool to fulfil these requirements. In this work, asymmetric electrospun polycaprolactone (PCL)-based nanofibers (NFs) were decorated with electrosprayed poly(lactic-co-glycolic acid) microparticles (PLGA MPs) containing the natural antibacterial compound thymol (THY) in order to obtain drug eluting antimicrobial dressings having sustained release. The synthesized dressings successfully inhibited the in vitro growth of Staphylococcus aureus ATCC 25923, showing also at the same doses cytocompatibility on human dermal fibroblasts and keratinocyte cultures after treatment for 24 h, which was not observed when using free thymol. An in vivo murine excisional wound splinting model, followed by the experimental infection of the wounds with S. aureus and their treatment with the synthesized dressings, pointed to the reduction of the bacterial load in wounds after 7 days, though the total elimination of the infection was not reached. The findings indicated the relevance of the direct contact between the dressings and the bacteria, highlighting the need to tune their design considering the wound surface and the nature of the antimicrobial cargo contained.
000102241 536__ $$9info:eu-repo/grantAgreement/EC/FP7/614715/EU/A Photo-triggered On-demand Drug Delivery System for Chronic Pain/NANOHEDONISM$$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2014-52384-R
000102241 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000102241 590__ $$a5.571$$b2020
000102241 591__ $$aPHARMACOLOGY & PHARMACY$$b48 / 275 = 0.175$$c2020$$dQ1$$eT1
000102241 592__ $$a1.103$$b2020
000102241 593__ $$aBiotechnology$$c2020$$dQ1
000102241 593__ $$aPharmaceutical Science$$c2020$$dQ1
000102241 593__ $$aMedicine (miscellaneous)$$c2020$$dQ1
000102241 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000102241 700__ $$0(orcid)0000-0002-0595-5514$$aGarcía-Salinas, S.$$uUniversidad de Zaragoza
000102241 700__ $$aSalido, S.
000102241 700__ $$0(orcid)0000-0001-8762-5457$$aSancho-Albero, M.$$uUniversidad de Zaragoza
000102241 700__ $$0(orcid)0000-0002-6275-1104$$aAndreu, V.
000102241 700__ $$0(orcid)0000-0002-8133-2124$$aPérez, M.$$uUniversidad de Zaragoza
000102241 700__ $$0(orcid)0000-0002-2053-9842$$aLuján, L.$$uUniversidad de Zaragoza
000102241 700__ $$0(orcid)0000-0002-2966-9088$$aIrusta, S.$$uUniversidad de Zaragoza
000102241 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, M.$$uUniversidad de Zaragoza
000102241 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, G.$$uUniversidad de Zaragoza
000102241 7102_ $$11001$$2025$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Anatom.Anatom.Patológ.Com
000102241 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000102241 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000102241 7102_ $$15005$$2790$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Tecnologi. Medio Ambiente
000102241 773__ $$g152 (2020), 327-339$$pEur. j. pharm. biopharm.$$tEuropean Journal of Pharmaceutics and Biopharmaceutics$$x0939-6411
000102241 8564_ $$s1091465$$uhttps://zaguan.unizar.es/record/102241/files/texto_completo.pdf$$yPostprint
000102241 8564_ $$s1121269$$uhttps://zaguan.unizar.es/record/102241/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000102241 909CO $$ooai:zaguan.unizar.es:102241$$particulos$$pdriver
000102241 951__ $$a2021-09-02-09:57:42
000102241 980__ $$aARTICLE